Hosted at nonprofit incubator and accelerator Winston Starts, The Founders’ Journey focused on venture-backed biotechnology ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Two former FDA leaders look at Commissioner Marty Makary’s early stumbles — and lay out a list of priorities to protect both ...

I have included these companies as, firstly, their share price performance in Q1 has been not dissimilar to a volatile early stage biotech ... % premium to the prior day's market closing price ...

April 21 - Tempest Therapeutics: Days after starting ... in Encoded's technology and early-stage R&D functions. Story Feb. 11 - Inventiva: Low on cash, the French biotech told its workers council ...

Donald Trump's unpredictable tariff policies have unsettled the venture capital world, further darkening an already gloomy ...

The U.S.-based biotechnology company is also known for ... Two of the dire wolves were born late last year, while the third arrived in early 2025. All three live in a secure 2,000-acre nature ...

highlighting significant improvements in first-day performance for its next-generation cont Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market ...

Companies that lead with purpose need metrics that actually track it.

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and genome duplication collide.

Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.